Riskpilot← Back to searchSign inGet full accessRaaven Therapeutics AB
ABActiveOrg 5593734063Runstensvägen 5Research and experimental development on natural sciences and engineering · NACE 7210Est. 20226 employees
Revenue 2024
SEK 13,7M
+204% vs 2023
EBITDA margin
21.2%
+424% vs 2023
Equity ratio
60.7%
Financial strength
Net profit 2024
SEK 2,3M
+660% vs 2023
| Revenue | SEK 13,7M | +204% |
| EBITDA | SEK 2,9M | +424% |
| Net profit | SEK 2,3M | +660% |
| Total assets | SEK 4,6M | +220% |
| Equity | SEK 2,8M | +487% |
| Employees | 6 | — |
Legal name
Raaven Therapeutics AB
Org number
5593734063
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
31 mars 2022
Share capital
SEK 25 000
Employees
6 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Davidsson, Staffan Marcus
Company purpose
Bolaget ska bedriva verksamhet inom forskning, utveckling, rådgivning, undervisning och förtroendeuppdrag inom det medicinska området och därmed förenlig verksamhet.
Address
Runstensvägen 5
Email
marcus.davidsson@raaven.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 2 097 | 4 488 | 13 652 |
| Staff expenses | −1 052 | −1 780 | −2 882 |
| EBITDA | 270 | 551 | 2 892 |
| Depreciation & amort. | — | — | −14 |
| EBIT | 270 | 551 | 2 878 |
| Net financials | 0 | 1 | 81 |
| Profit before tax | 195 | 402 | 2 959 |
| Tax | −49 | −96 | −637 |
| Net profit | 146 | 306 | 2 322 |
| Item | 2022 | 2023 | 2024 |
|---|---|---|---|
| Total assets | 997 | 1 443 | 4 614 |
| Equity | 171 | 477 | 2 799 |
| Long-term debt | — | — | — |
| Short-term debt | 751 | 742 | 1 591 |
| Total debt | 751 | 742 | 1 591 |
EBITDA margin
21.2%
This company
15.8%
Market median
+34% vs market
20222024
Equity ratio
60.7%
This company
38.2%
Market median
+59% vs market
20222024
Return on equity
83.0%
This company
18.4%
Market median
+351% vs market
20222024
Net profit margin
17.0%
This company
8.1%
Market median
+110% vs market
20222024
Asset turnover
2.96×
This company
1.12×
Market median
+164% vs market
20222024
Debt / equity
0.65×
This company
0.62×
Market median
+5% vs market
20222024
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
BR | Audit | 2022 |
SM Chief Executive Officer | Chief Executive Officer | 2025 |
| Former (1) | ||
KM Chief Executive Officer | Chief Executive Officer | 2024 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 88% | 88% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Marcus Davidsson Consulting AB
Raaven Therapeutics AB Board members of Raaven Therapeutics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karl Magnus Kristian Henriks | Chief Executive Officer | 0 companies |
| Bengt Roland Andersson | Audit | 0 companies |
| Staffan Marcus Davidsson | Chief Executive Officer | 0 companies |
| Lena Mårtensson Wernrud | Board of Directors | 0 companies |
| Per Tore Erik Wilander | Chairman | 0 companies |
| Henrik Andreas Davidsson | Deputy Board Member | 0 companies |